YouTube · Q2 2026 · 2026-07-31
SNY · NasdaqGS
Sanofi
Drug Manufacturers - General · France
USD 42.48-1.5% daily changeQuote 2026-09-18 · USD
- Market cap (USD)
- US$101.79B
- Trailing P/E
- 22.96x
- Forward P/E
- 7.84x
- Quarterly revenue growth
- 14.6%
- Trailing net margin
- 8.1%
- Indicated dividend yield
- 5.7%
Snapshot 2026-09-20 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-30 (provider estimate, not issuer-confirmed).
Company background
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Company websiteQ2 2026
Go beyond the headline.
Sanofi (SNY): Sales +18%, Guidance RAISED — the Stock FELL. Is SNY Stock a Buy?
Published 2026-08-02
Comparable businesses
SNY peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | SNYSanofiSnapshot 2026-09-20Financial period: 2026-06-30 | BMYBristol-Myers Squibb CompanySnapshot 2026-09-20Financial period: 2026-06-30 | PFEPfizer Inc.Snapshot 2026-09-20Financial period: 2026-06-28 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$101.79B | US$128.81B | US$157.65B | US$143.23Bn=2 |
| Forward P/EProvider forward earnings estimate | 7.84x | 9.61x | 9.55x | 9.58xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | — | 8.60x | 8.26x | 8.43xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 14.6% | 5.7% | 2.6% | 4.2%n=2 |
| Operating marginLatest reported quarter | 21.0% | 34.4% | 27.9% | 31.1%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | — | 6.3% | 7.9% | 7.1%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 1.27x | 1.80x | 2.04x | 1.92xn=2 |
| Debt / equityTotal debt / positive book equity | 0.34x | 2.02x | 0.74x | 1.38xn=2 |
| Trailing P/ETrailing twelve-month earnings | 22.96x | 13.89x | 36.39x | 25.14xn=2 |
| Price / bookPrice / positive book equity per share | 1.26x | 5.77x | 1.85x | 3.81xn=2 |
| EV / salesEnterprise value / trailing revenue | — | 3.31x | 3.29x | 3.30xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | -91.2% | 153.1% | — | — |
| Gross marginTrailing twelve months | 73.5% | 71.7% | 74.7% | 73.2%n=2 |
| Net marginTrailing twelve months | 8.1% | 18.9% | 6.8% | 12.8%n=2 |
| Return on equityProvider trailing return; positive equity only | 5.7% | 46.6% | 5.0% | 25.8%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 12.9% | 16.5% | 19.6% | 18.0%n=2 |
| Dividend yieldIndicated annual dividend / price | 5.7% | 4.0% | 6.2% | 5.1%n=2 |
| Earnings payoutProvider trailing dividend payout | 128.2% | 55.3% | 226.3% | 140.8%n=2 |
| Current ratioCurrent assets / current liabilities | 0.99x | 1.53x | 1.27x | 1.40xn=2 |
| BetaProvider historical market sensitivity | 0.28 | 0.23 | 0.30 | 0.26n=2 |
YouTube · Q2 2026 · 2026-07-31
YouTube · Q2 2026 · 2026-08-06
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for SNY
Q2 20262026-08-02
Sanofi (SNY): Sales +18%, Guidance RAISED — the Stock FELL. Is SNY Stock a Buy?
Presentation · 2026-08-02 · YouTube